Cytarabine-resistant (640nM) acute myeloid leukemia (AML) MOLM-13 cell line
- Name Disha Malani ; Olli Kallioniemi
- Institute University of Helsinki
Tool name: Cytarabine-resistant (640nM) acute myeloid leukemia (AML) MOLM-13 cell line
Tool type: Cell Lines
Tool sub-type: Continuous
Parental cell line: MOLM-13
Cancer type: Acute myeloid leukemia, cytarabine-resistance, AML, chemotherapy resistance
Description: Acute myeloid leukaemia (AML) is a cancer of the myeloid line of blood cells, characterised by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Cytarabine is a common chemotherapy treatment for AML. Resistance to it in AML cells was shown to be linked to aberrant expression of equilibrative nucleoside transporters (ENT1) and metabolic enzymes deoxycytidine kinase (DCK) and cytosolic 5'-nucleotidase-II (NT5C2). The MOLM-13 cell line was derived from the peripheral blood of a patient at relapse of acute monocytic leukaemia.
Research area: Cancer
- For Research Use Only
- • Malani et al. 2017. Leukemia. 31(5):1187-1195. PMID: 27833094.